Effect of Combinations of Mycobacteriophages and Drugs against Mycobacterium Spp.

Rajitha Satish; Anita Desouza

Authors

Rajitha Satish
Anita Desouza

phage therapy; mycobacteriophages; combination therapies

Abstract

The emergence of multidrug-resistant tuberculosis (MDR-TB) is a matter of global concern. The use of mycobacteriophages alone or in combination with antibiotics could be used as an alternative approach to treat drug-resistant Mycobacteria. The aim of the study was the evaluation of the effect of an isolated mycobacteriophage in combination with Isoniazid, Rifampicin, Streptomycin, and Ampicillin against Mycobacterium tuberculosis and Mycobacterium smegmatis. Determination of the MIC of the above drugs for each strain was done by the standard tube dilution method. Further, the inhibitory effect of varying drug concentrations in combination with different dilutions of the mycobacteriophage was studied. The growth inhibition pattern for both the organisms was also studied in the presence of different dilutions of mycobacteriophage by turbidometric and resazurin dye reduction method. The killing pattern of drugs, at concentrations below the MIC, when combined with mycobacteriophage, was determined. The phage induced lysis of bacteria assisted in decreasing the inhibitory concentration of the drugs.

Downloads

How to Cite

Effect of Combinations of Mycobacteriophages and Drugs against Mycobacterium Spp. (2020). Global Journal of Science Frontier Research, 19(B3), 1-19. https://www.journalofscience.org/index.php/GJSFR/article/view/2576

Download Citation

References

Stephen Abedon, Sarah Kuhl, Bob Blasdel, Elizabeth Kutter (2011) Phage treatment of human infections. 1(2), 66-85.

Stephen Abedon, Cameron Thomas-Abedon (2010) Phage Therapy Pharmacology. 11(1), 28-47.

Suhail Ahmad (2010) New approaches in the diagnosis and treatment of latent tuberculosis infection. 11(1), 169-185.

J Caminero, G Sotgiu, A Zumla, G Migliori (2010) Best drug treatment for multidrugresistant and extensively drug-resistant tuberculosis. 10, 621-629.

Rebekah Dedrick, Carlos Guerrero-Bustamante, Rebecca Garlena, Daniel Russell, Katrina Ford, Kathryn Harris, Kimberly Gilmour, James Soothill, Deborah Jacobs-Sera, Robert Schooley, Graham Hatfull, Helen Spencer (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. 25(5), 730-733.

J Dinnes, J Deeks, H Kunst, A Gibson, E Cummins, N Waugh, F Drobniewski, A Lalvani (2007) A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. 11(3), 1-196.

V Gondil, S Chhibber (2018) Exploring potential of phage therapy for tuberculosis using model organism. 2, 9-15.

Shuliang Guo, A Zhi (2012) Phage in the diagnosis and treatment of tuberculosis. 17(7), 2691.

Graham Hatfull (2014) Mycobacteriophages: Windows into Tuberculosis. 10(3), e1003953.

G Hatfull (2012) The secret lives of mycobacteriophages. 82, 179288.

V Leimane, V Riekstina, T Holtz, E Zarovska, V Skripconoka, L Thorpe, K Laserson, C Wells (2005) Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. 365, 318-326.

D Lin, B Koskella, H Lin (2017) Phage therapy: An alternative to antibiotics in the age of multidrug-resistance. 8(3), 162-173.

P Li, L Yong-Ai, C Bao Wen, L Youlun, S Xiaobing, S Cheng, W Guozhi (2009) Therapeutic effect of bacteriophage D29 in the treatment for 26: Growth curve of M.smeg in the presence of phage Figure guinea pigs infected with sensitive strain of Mycobacterium tuberculosis. 25(08), 733-736.

Shigenobu Matsuzaki, Mohammad Rashel, Jumpei Uchiyama, Shingo Sakurai, Takako Ujihara, Masayuki Kuroda, Shosuke Imai, Masahiko Ikeuchi, Toshikazu Tani, Mikiya Fujieda, Hiroshi Wakiguchi (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. 11(5), 211-219.

C Merril, B Biswas, R Carlton, N Jensen, G Creed, S Zullo, S Adhya (1996) Long-circulating bacteriophage as antibacterial agents.. 93(8), 3188-3192.

J Pereira, H David, N Rastogi (1983) Isolation and partial characterization of temperaturesensitive mutants of the mycobacteriophage D29. 134, 33-49.

Welkin Pope, Christina Ferreira, Deborah Jacobs-Sera, Robert Benjamin, Ariangela Davis, Randall Dejong, Sarah Elgin, Forrest Guilfoile, Mark Forsyth, Alexander Harris, Samuel Harvey, Lee Hughes, Peter Hynes, Arrykka Jackson, Marilyn Jalal, Elizabeth Macmurray, Coreen Manley, Molly Mcdonough, Jordan Mosier, Larissa Osterbann, Hannah Rabinowitz, Corwin Rhyan, Daniel Russell, Margaret Saha, Christopher Shaffer, Stephanie Simon, Erika Sims, Isabel Tovar, Emilie Weisser, John Wertz, Kathleen Weston-Hafer, Kurt Williamson, Bo Zhang, Steven Cresawn, Paras Jain, Mariana Piuri, William Jacobs, Roger Hendrix, Graham Hatfull (2011) Cluster K Mycobacteriophages: Insights into the Evolutionary Origins of Mycobacteriophage TM4. 6(10), e26750.

S Samaddar, R Grewal, S Sinha, S Ghosh, S Roy, S Das Gupta (2016) Dynamics of Mycobacteriophage-Mycobacterial Host Interaction: Evidence for Secondary Mechanisms for Host Lethality. 82(1), 124-133.

Rajitha Satish, Anita Desouza (2019) Study of characteristics of mycobacteriophage - A novel tool to treat Mycobacterium spp.. 8(2), 170.

R Satish, A Desouza (2018) Isolation of Mycobacteriophage Novel tool to treat Mycobacterium spp. 5(2), 46-50.

N Shah, Abigail Wright, Gill-Han Bai, Lucia Barrera, Fadila Boulahbal, Nuria Martín-Casabona, Francis Drobniewski, Chris Gilpin, Marta Havelková, Rosario Lepe, Richard Lumb, Beverly Metchock, Françoise Portaels, Maria Rodrigues, Sabine Rüsch-Gerdes, Armand Van Deun, Veronique Vincent, Kayla Laserson, Charles Wells, J Cegielski (2007) Worldwide Emergence of Extensively Drug-resistant Tuberculosis. 13(3), 380-387.

Alexander Sulakvelidze, Zemphira Alavidze, J Morris (2001) Bacteriophage Therapy. 45(3), 649-659.

Yasunori Tanji, Takuya Shimada, Hiroshi Fukudomi, Kazuhiko Miyanaga, Yutaka Nakai, Hajime Unno (2005) Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. 100(3), 280-287.

Y Tanji, T Shimada, M Yoichi, K Miyanaga, K Hori, H Unno (2004) Toward rational control of Escherichia coli O157:H7 by a phage cocktail. 64(2), 270-274.

Christal Vitiello, Carl Merril, Sankar Adhya (2005) An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. 114(1-2), 101-103.